Biogen (BIIB) Tops Q3 EPS by 71c, Updates Guidance, Approves $5 Billion Buyback
Tweet
Share
E-mail
Get Alerts BIIB Hot Sheet
Price: $201.99 +4.56%
EPS Growth %: +7.9%
Financial Fact:
Amortization of acquired intangible assets: 99.7M
Today's EPS Names:
NLY, CP, RUSHA, More
EPS Growth %: +7.9%
Financial Fact:
Amortization of acquired intangible assets: 99.7M
Today's EPS Names:
NLY, CP, RUSHA, More
Join SI Premium – FREE
(Updated - October 21, 2020 7:06 AM EDT)
Biogen (NASDAQ: BIIB) reported Q3 EPS of $8.84, $0.71 better than the analyst estimate of $8.13. Revenue for the quarter came in at $3.38 billion versus the consensus estimate of $3.35 billion.
GUIDANCE:
Biogen sees FY2020 EPS of $32.50-$33.50, versus the consensus of $34.77.
- Company announces new $5.0 billion share repurchase authorization
For earnings history and earnings-related data on Biogen (BIIB) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Biogen (BIIB) tops earnings expectations but revenue falls short
- SLM (SLM) Tops Q1 EPS by 20c; offers guidance
- Core Laboratories (CLB) Misses Q1 EPS by 13c
Create E-mail Alert Related Categories
Earnings, Guidance, Hot Buybacks, Hot Earnings, Hot Guidance, Stock BuybacksRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
